drugset / Trial / NCT05480579
A Study of IBI311 in Healthy Volunteers
RandomizedSequentialDouble-blindTreatment
Summary
It is designed for Multi-center, double-masked, randomized, placebo- control study with dose escalation phase I trial to evaluate the safety, tolerability, PK and immunogenicity profiles of a single intravenous injection of IBI311 in healthy volunteers.
Timeline
- Start
- 2022-08-10
- Primary completion
- 2022-11-23
- Completion
- 2023-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teprotumumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.